Form 4: Director Alan Colman Acquires 12,000 VNRX Shares

VolitionRx Director Alan Colman reported the acquisition of 12,000 common shares through the vesting of restricted stock units.

Summary

• Director Alan Colman acquired 12,000 shares of VolitionRx Ltd. common stock on January 22, 2026.
• The acquisition resulted from the vesting of Restricted Stock Units (RSUs) that were initially awarded on March 17, 2025, under the Issuer's 2024 Stock Incentive Plan.
• Out of an initial award of 40,000 RSUs, 12,000 units vested due to the achievement of certain corporate performance goals on or prior to June 30, 2025, and December 31, 2025.
• The remaining 28,000 RSUs did not vest and were subsequently cancelled on June 30, 2025, and January 22, 2026.
• The 12,000 vested RSUs are subject to a 3-year time-based vesting schedule, with three equal installments of 4,000 units vesting on March 17, 2026, March 17, 2027, and March 17, 2028, respectively.
• Upon vesting and settlement, the reporting person will receive shares of common stock equal to the number of vested RSUs.
• Following this reported transaction, Alan Colman directly beneficially owns 257,364 shares of VolitionRx Ltd. common stock.

Sentiment

Score: 6

Explanation: The vesting of 12,000 RSUs indicates the achievement of some corporate performance goals and increases director ownership, which is generally positive. However, the cancellation of 28,000 RSUs suggests other performance targets were not met, tempering the overall sentiment.

Positives

• A portion of the restricted stock units (12,000 out of 40,000) vested, indicating the achievement of certain corporate performance goals.
• Director Alan Colman's beneficial ownership increased by 12,000 shares, further aligning his interests with those of shareholders.

Negatives

• A significant portion (28,000 out of 40,000) of the awarded restricted stock units did not vest and were cancelled, suggesting that some performance goals were not met.

Future Outlook

The filing indicates future vesting events for the 12,000 RSUs, with installments scheduled for March 17, 2026, 2027, and 2028, which will result in additional common stock acquisitions for the reporting person.

Industry Context

NA

Related Party Transactions

• The acquisition of shares by Director Alan Colman through the vesting of restricted stock units is a compensation-related transaction under the company's 2024 Stock Incentive Plan.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with shareholders due to increased direct ownership.
• Employees (specifically management): Reflects the execution of executive compensation plans tied to performance.

Next Steps

• Future vesting of 4,000 common shares on March 17, 2026.
• Future vesting of 4,000 common shares on March 17, 2027.
• Future vesting of 4,000 common shares on March 17, 2028.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction related to the vesting of restricted stock units for a director. While it shows some performance goals were met, a significant portion of the RSUs were cancelled. This type of filing typically does not provide enough information to warrant a change in investment recommendation, thus a 'hold' stance is maintained, pending more comprehensive financial disclosures.

Keywords

VolitionRx, VNRX, Alan Colman, Director, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Incentive Plan, Beneficial Ownership